Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Philips (NYSE: PHG) and WellSpan Health announced a seven-year strategic alliance covering Central Pennsylvania and Northern Maryland. The collaboration combines research, co-development and a long-term commercial agreement.
It includes AI-enabled imaging and diagnostics, co-created products, and lifecycle-managed Philips equipment across 12 WellSpan hospitals and outpatient sites to enhance care and operational efficiency.
Philips (NYSE: PHG) announced that its Lumea IPL 9000 Series and Philips Sonicare 6400 were named winners in the Good Housekeeping 2026 Beauty Awards, in the skin-boosting body care and smile refresher categories.
Lumea IPL reports over 90% hair reduction in three sessions2, while Sonicare 6400 is reported to remove up to 1000% more plaque than manual brushing4. Lumea IPL is sold exclusively on Amazon for an MSRP of $579.99; Sonicare 6400 is sold exclusively at Walmart for an MSRP of $110.00.
Philips (NYSE: PHG) received FDA 510(k) clearance for Elevate Plus on its EPIQ Elite and Affiniti ultrasound systems, adding AI-powered workflow and imaging enhancements. Elevate Plus, which also has CE Mark, offers Auto Measure Abdomen with over 93% accuracy and reported scanning time reductions of up to 30%.
Integrated Koios AI decision support enables rapid Bi-RADS and Ti-RADS lesion classification, while new imaging tools like XRes Pro+ and Super Res MVI Pro support clearer visualization. A modular, upgradable platform aims to extend system lifespan and support remote updates and tele-health workflows.
Philips (NYSE: PHG) set the 2025 dividend exchange ratio at 1 new share for every 26.9341 existing shares. The ratio is based on a volume-weighted average price of EUR 22.8640, targeting a gross dividend value of approximately EUR 0.85 per share.
Philips will issue 19,964,655 new common shares, bringing total shares to 982,884,787 and total issued share capital to EUR 196,576,957.40. Shareholders could choose shares or cash; the aggregate cash election was 43.8%. Dividend payment and share delivery start from June 3, 2026.
Philips (NYSE: PHG) and Disney (NYSE: DIS) are integrating Disney stories and characters into Philips Ambient Experience for MRI in 87 countries to support children during scans.
According to Philips, a European multicenter study found 43% lower stress and 63% fewer scan pauses in children aged 6–10 using this child-friendly, immersive set-up.
Philips (NYSE:PHG) will highlight new imaging, physiology and AI-enabled guidance solutions for complex PCI and structural heart procedures at EuroPCR 2026 in Paris.
Showcased technologies include SmartIQ ultra-low-dose imaging, IntraSight Plus, DeviceGuide, VeriSight Pro 3D ICE and Hemo R2, all aimed at unified workflow and radiation dose reduction.
Philips (NYSE:PHG) introduced SmartIQ, a coronary imaging technology for Azurion systems, designed to improve image quality while optimizing radiation and contrast dose. An ultra-low dose protocol for coronary procedures employs over 50% less X-ray radiation than the lowest ClarityIQ settings.
SmartIQ is CE-marked and available on new and existing Azurion systems in Europe and selected markets, with initial pilot data suggesting higher image quality at maintained or reduced radiation and contrast dose. The ongoing RADIQAL trial has reached 60% enrollment; SmartIQ is not yet cleared in the United States.
Philips (NYSE: PHG) and partners Cuviva and Vingmed were selected by Region Stockholm, via a Karolinska University Hospital-led tender, to deliver an advanced hospital-at-home program for up to 15,000 complex or chronic patients annually.
The up to eight-year agreement covers more than 2 million residents, using remote monitoring, vital-sign tracking, video consultations and secure chat to extend hospital-level oversight into patients’ homes and help ease pressure on hospitals and clinical staff.
Royal Philips (NYSE: PHG) reported that shareholders approved all proposals at the Annual General Meeting on May 8, 2026. Resolutions included the appointment of John DeFord to the Supervisory Board, re-appointments of three supervisory members, and re-appointment of Roy Jakobs as President/CEO and Chairman.
Shareholders also discharged the Board of Management and Supervisory Board. Philips referenced its Annual Report 2025 for financial statements and provided links for dividend and board composition details.
Summary not available.